Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical Stem Cell and NK Cell Transplant for Infants with Hematologic Malignancies
NCT00145626Phase 2Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- May 2004
- Primary completion
- Mar 2015
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Natural Killer Cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS) and 2 more, sponsored by St. Jude Children's Research Hospital. Primary endpoint: One-year Survival at 1 year. Started May 2004; status: completed.
02
Drugs
Natural Killer Cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndromes (MDS)chronic myeloid leukemia (CML)histiocytosis
Beyond the preview
Go deeper on NCT00145626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00145626.